About NOXXON
NOXXON’s oncology-focused pipeline acts on the cancer immunity cycle by breaking the tumor protection barrier, blocking tumor repair and exposing hidden tumor cells. Through neutralizing chemokines in the tumor micro-environment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, lead program NOX-A12 will deliver top-line data from a combination trial with the immuno-oncology checkpoint inhibitor, Keytruda®, in metastatic colorectal and pancreatic cancer patients in 2018.
| 2018, April 10 - Check out our latest analyst report by Aurgalys Value |
Press ReleaseBerlin, Germany
2018, April 10 8:00 a.m NOXXON announces initiation of analyst coverage by Aurgalys 2018, March 22 9:00 p.m NOXXON announces convocation of an extra-ordinary general meeting of shareholders 2018, March 13 8:00 a.m NOXXON renegotiates ODIRNANE BSA financing agreement to remove unilateral option for investor to subscribe for tranches and to cancel existing warrents |
EventsAram Mangasarian, Jarl Ulf Jungnelius, Dirk Eulberg, Anna Frömming May 8-9, New York, USA Aram Mangasarian |